| Date | Title | Description |
| 11.05.2023 | Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting | Lead program, IG-002 targeting ABCA4 retinopathies demonstrated long-term, persistent protein expression over twelve months with a single administration
Newly developed in vitro efficacy model highlights ability of non-viral gene therapy p... |
| 11.05.2023 | Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting | Lead program, IG-002 targeting ABCA4 retinopathies demonstrated long-term, persistent protein expression over twelve months with a single administration |
| 20.01.2022 | Intergalactic Therapeutics Announces Scientific Advisory Board Membership | BOSTON, Mass., January 20, 2022/PR NEWSWIRE/ -- Intergalactic Therapeutics, a focal non-viral gene therapy company, has announced members of its Scientific Advisory Board (SAB): Sangeeta Bhatia, M.D., Ph.D., Thaddeus Dryja, M.D., Rachel Huc... |
| 20.01.2022 | Intergalactic Therapeutics Announces Scientific Advisory Board Membership | BOSTON, Mass., January 20, 2022/PR NEWSWIRE/ -- Intergalactic Therapeutics, a focal non-viral gene therapy company, has announced members of its Scientific Advisory Board (SAB): Sangeeta Bhatia, M.D., Ph.D., Thaddeus Dryja, M.D., Rachel Huc... |
| 20.01.2022 | Intergalactic Therapeutics Announces Scientific Advisory Board Membership | BOSTON, Jan. 20, 2022 /PRNewswire/ -- Intergalactic Therapeutics, a focal non-viral gene therapy company, has announced members of its Scientific Advisory Board (SAB): Sangeeta Bhatia, M.D., Ph.D., Thaddeus Dryja, M.D., Rachel Huckfeldt, M.... |
| 07.10.2021 | ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding | NEW YORK and BOSTON, Mass., October 7, 2021/PR NEWSWIRE/ – ATP, a leader in life sciences venture capital, today debuted Intergalactic Therapeutics, a non-viral gene therapy platform led by a top management team and funded with $75 million ... |
| 07.10.2021 | ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding | NEW YORK and BOSTON, Mass., October 7, 2021/PR NEWSWIRE/ – ATP, a leader in life sciences venture capital, today debuted Intergalactic Therapeutics, a non-viral gene therapy platform led by a top management team and funded with $75 million ... |
| 07.10.2021 | Intergalactic Therapeutics Inks $75M Series A |
BOSTON, MA, Intergalactic Therapeutics raises $75 million in Series A funding.
>> Click here for more funding data on Intergalactic Therapeutics
>> To export Intergalactic Therapeutics funding data to PDF and Excel, click he... |
| 07.10.2021 | Intergalactic Therapeutics Raises $75M in Series A Funding | Intergalactic Therapeutics, a Boston, MA-based non-viral gene therapy platform, raised $75m in Series A financing.
ATP, a life sciences venture capital firm, made the founding investment.
Intergalactic’s breakthrough approach to non-viral g... |
